Publication abstract
Subject class: Biotech, Life Sciences, Business Development, Funding
Genomics & Proteomics in Drug Discovery – ABA 210
Huckle D
Adams Business Associates: Global Library of World, National and Regional in depth Information and Market Analyses.
(225 pages & 104 figures, plus 2003 & 2005 addenda). Price: GB £ 1,900 [single site licence], GB £ 2,700 [Multi-site licence)
Target audience: Chief executives, marketing and sales managers, business development managers, investors and analysts.
This is a primary report from a library of Global, National and Regional Analyses.
This report covers the Reagents, Services and Equipment used in the key fields of Genomics and Proteomics with special reference to Drug Discovery as
the driver of the main sectors of Life Science and Biotechnology.
The primary objective of the report is to identify the new philosophy in Drug Discovery and how modern molecular technologies have changed the approaches can help to address the current economic pressures and predict future issues for business development in the Pharma industry.
In addition to detailing the products and their uses the global markets are quantified and described in detail by region and country as well as by research segment. The major suppliers in each product sector are examined with detailed profiles of the major international suppliers in each of the product sectors.
Written in September 2002 this report now also contains two supplements for all key charts and for changes within the market as of October 2003 and September 2005. The commercial information is also updated in these Supplements to ensure the Report retains its immediate utility.
The Life Science research market is strongly led by the impact of Drug Discovery and the need to develop Pharmaceutical procedures to enhance the speed of Drug Development and cost efficiency. Trends and Issues, Market Segmentation by Country or Region, Applications or customers are explained within the multi layered Life Sciences sector.
The Report is now integrated with the Life Science Funding Report (see ABA 225) and the BioInformatics Report (see ABA 215) into the fully reanalysed report for Global Healthcare Funding & Life Science Business, ABA 305.